NovaBridge Biosciences (NBP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NovaBridge Biosciences, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NovaBridge Biosciences (NBP) has returned -38.19% so far this year and 198.58% over the past 12 months.

Based on dividend-adjusted daily data since Jan 17, 2020, NBP's average daily return is +0.07%, while the average monthly return is +0.70%. At this rate, your investment would double in approximately 8.3 years.

Historically, 44% of months were positive and 56% were negative. The best month was Aug 2025 with a return of +107.0%, while the worst month was Jan 2022 at -46.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.

On a daily basis, NBP closed higher 45% of trading days. The best single day was Jun 3, 2025 with a return of +46.1%, while the worst single day was Jun 26, 2025 at -27.3%.

NovaBridge Biosciences has an annualized alpha of 5.00%, beta of 0.90, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 21, 2020.

• This stock participated in 178.48% of S&P 500 Index downside but only 64.67% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NBP ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for NovaBridge Biosciences (NBP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NovaBridge Biosciences. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NovaBridge Biosciences was 99.27%, occurring on Apr 7, 2025. The portfolio has not yet recovered.

The current NovaBridge Biosciences drawdown is 97.09%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NovaBridge Biosciences over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NovaBridge Biosciences is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.